2012 fnih annual report

COLLABORATIONFOR INNOVATION

2012 ANNUAL REPORT

Table of Contents

SCIENCE ....................................................... 2

TRAINING AND EDUCATION ..................... 10

EVENTS........................................................14

FUNDS AND ENDOWMENTS .................... 16

DONORS AND GIVING SOCIETIES ........... 21

FINANCIALS ............................................... 26

STAFF AND BOARD OF DIRECTORS........ 28

Foundation for the National Institutes of Health WWW.FNIH.ORG | 1

Letter from the Chairman

ria Freire, who joined us November 1st, as FNIH President and reire, who joined usreire, who joined usI am pleased to welcome Dr. Maria FI am pleased to welcome Dr. Maria F

ing as President of the Albert and Mary Lasker Foundation,as Presidas PresidExecutive Director. Most recently serving Executive Director. Most recently serving

mplishments in health research on a global scale. Dr. Freire’s career is remarkable in its accompliDr. Freire’s career is remarkable in its accompli

ation with the National Institutes of Health (NIH),Dr. Freire enjoys a long associationDr. Freire enjoys a long association

ansfer from 1995 to 2001 and serving as adirecting its Office of Technology Transfdirecting its Office of Technology Transf

e NIH Director from 2008 to 2012. Thismember of the Advisory Committee to the NIHmember of the Advisory Committee to the NIH

fulfill our mission to support the established relationship will enrich our ability to fulfiestablished relationship will enrich our ability to fulfi

NIH on many levels.NIH on many levels.

ion of partners fromIn 2012, our portfolio of work embraced a broad constellation In 2012, our portfolio of work embraced a broad constellation

nonprofit sector as well asrofit serofit semany institutes and centers within the NIH, from the nonmany institutes and centers within the NIH, from the non

echnology, retail, and food and ogy, retail, aogy, retail, athe private sector, including pharmaceutical, technthe private sector, including pharmaceutical, techn

ons as diverse as the National Footballdiverse as the Natdiverse as the Natbeverage industries and from organizations abeverage industries and from organizations a

League and Google.League and Google.

as a trusted, neutral convener remains fundamental rusted, neutral convener remains rusted, neutral convener remains As we expand and refine activities, our role as aAs we expand and refine activities, our role as a

e do. This pivotal position enables us to channel expertise, This pivotal position enables us to channThis pivotal position enables us to channto who we are and integral to what we doto who we are and integral to what we do

resources and funds from multiple and diverse partners to address common challenges efficiently,d diverse partners to address common challed diverse partners to address common challeesources and funds from multiple aesources and funds from multiple a

effectively and ethically. In doing so, we ensure that the sum of our efforts is greater than their g so, we ensure that the sum of our efforts is greateg so, we ensure that the sum of our efforts is greatevely and ethically. In dovely and ethically. In do

discrete parts. In short, the FNhe FNIH promotes collaboration for innovation.he FNIH promotes collaboration for innovation.ts. In short, ts. In short,

rles A. Sanders, M.D.

ateful to the“It is a great honor to head this remarkable organization. I am gra“It is a great honor to head this remarkable organization. I am gra

look forward FNIH Board, staff, partners and funders for this opportunity and FNIH Board, staff, partners and funders for this opportunity and

to working with all in the years to come.” to working with all in the years to come.”

Maria C. Freire, Ph.D.,Maria C. Freire, Ph.D.,

President and Executive DirectorPresident and Executive Director

Charles A. Sanders, M.D.

Chairman

SCIENCE

“FNIH has demonstrated its ability to conduct

complex transactions quickly and efficiently.

Working with FNIH to pursue mutual goals shared

with the Bill & Melinda Gates Foundation’s CAVD

will expedite the Vaccine Research Center’s

development of novel passive-active strategies

for prevention of HIV infection.”

Gary Nabel, M.D., Ph.D., Senior Vice President for Global R&D, Sanofi; former Director of the Vaccine Research Center, NIAID


Sports and Health Research Program With a $30 million donation, the National

Football League (NFL) became the founding

partner of the FNIH’s new Sports and Health

Research Program. While specific initiatives

have yet to be finalized, potential areas of

research include brain injury, sudden cardiac

death, heat and hydration-related illness,

joint disease, health effects of performance-

enhancing substances and chronic pain.

Traumatic brain injury (TBI) is an important area

of interest for professional football and other

contact sports. Research, to better understand

ways to recognize and prevent brain injury, is

a major focus of discussions within this new

program. The impact of research on brain

injury will extend far beyond the NFL, as TBI

is the signature wound of soldiers fighting in

Iraq and Afghanistan, and each year, across

America, an estimated

1.7 million people suffer a brain injury due

to trauma.

The Sports and Health Research Program

aims to attract funding from other donors,

including additional sports organizations.

The founding grant represents the NFL’s

single largest donation to any organization

in the league’s 92 years.

Biomarkers Consortium A wide-ranging initiative to advance precision

(personalized) medicine, the Biomarkers

Consortium works to identify measurable

indicators of biological and pathological

processes to predict, prevent and treat

disease. Among the projects underway are:

I-SPY 2 Women newly diagnosed with aggressive

breast cancer should have more rapid access

to promising therapies thanks to new Food and

Drug Administration (FDA) draft guidelines (or

guidance) based on the FNIH I-SPY 2 study.

I-SPY 2, a project of the Biomarkers

Consortium, is pioneering a novel protocol

to test and gain approval for new drugs, a

process that is notoriously slow and expensive.

Currently, it can take more than a decade to

bring a new cancer drug to market at a cost of

Research: Program Highlights In 2012, FNIH programs encompassed a broad spectrum of biomedical research—from precise, innovative fundamental work to understand disease and its progression, to clinical and field trials to evaluate potential new therapeutic interventions, to large-scale methods to monitor the effects of existing medicines. Through FNIH, private-sector organizations with an interest in a disease or a new technology can team up with the NIH to accelerate the pathway from collaboration to innovation.

more than $1 billion—time many breast cancer

patients simply do not have.

The trial’s approach is groundbreaking in two

ways: first, it is screening various potential

new drugs within the same study; as these

candidate drugs are moved out—either for

next-stage testing or because they fail—new

ones are introduced. Second, instead of a

one-size-fits-all trial, candidate drugs are

assigned to patients based on the specific

characteristics of their tumor.

The draft FDA guidance on the subject

suggests that once these new drugs have

shown clinical benefit in the I-SPY 2 model,

they should be eligible for accelerated

regulatory approval following a confirmatory

trial. The goal of I-SPY 2 is to cut the time to

develop a drug in half and dramatically lower

the costs.

Consensus Definition of Clinically Important Sarcopenia This Biomarkers project team has completed

its work in advancing the first evidence-based

definition of sarcopenia (muscle weakness), a

condition that results in serious consequences

such as disability and increased mortality.

In the first phase of the project, six principal

investigators analyzed pooled data from

clinical trials and large observational studies,

such as the Health ABC and Framingham

studies. Their findings, reported at a four-day

Sarcopenia Consensus Summit in May 2012,

are being readied for publication. The new

definition will assist researchers, clinicians

and regulators in diagnosing sarcopenia and

the consensus-building process will serve as

a model for articulating other evidence-based

definitions of geriatric health problems.

Several other Biomarkers Consortium projects marked significant milestones in 2012 as well:

Researchers on a diabetes project to identify

biomarkers that predict the performance

of insulin-producing cells in the pancreas

completed their studies of healthy, pre-

diabetic and diabetic patients and will

present findings at the American Diabetes

Association meeting in the summer of 2013.

A project team working to help researchers

develop drugs that minimize kidney injury

completed a retrospective analysis and

launched two clinical studies, together

enrolling 300 patients.

An atherosclerosis modeling project was

launched in September 2012. This two-year

effort will integrate existing biomarker data

into one comprehensive computer-based

disease model to identify which measures

best predict clinical outcomes such as heart

attack and stroke.

A project aimed at aiding the development of

new antibiotics against community-acquired

bacterial pneumonia and acute bacterial

skin infections entered its second phase.

The team published a paper in the journal

Clinical Infectious Diseases on its efforts

and progress to date. The clinical end points

established by this project have proven vital

to the approval of several antibacterial drugs.


Alzheimer’s Disease Neuroimaging Initiative 2 Now in its eighth year, the Alzheimer’s Disease

Neuroimaging Initiative (ADNI) is the largest

public-private brain research partnership to

date, with 28 private partners coordinated by

the FNIH. It remains the gold standard for how

such partnerships can advance biomedical

research. ADNI data, collected on the study’s

1,500 participants, is placed in the scientific

public domain to encourage its use by the

broadest range of investigators possible.

The accomplishments from this program

continue to inform development of new

therapies as well as influence additional

studies. Under the organization of the

Alzheimer’s Association’s World-Wide ADNI,

similar work is being carried out in Argentina,

China, Europe, Japan, Australia, Taiwan and

South Korea.

Building on the success of the program, ADNI

has garnered additional support from the

Brin Wojcicki Foundation and the Alzheimer’s

Association to conduct whole genome

sequencing on 818 study participants. This

effort will exponentially increase the amount

of genetic data available to investigators, likely

highlighting a wealth of new targets for risk

assessment, insights and therapies.

Complementary to the scope of ADNI, the

program’s investigators have received support

from the Department of Defense to follow 300

Vietnam veterans, aged between 60 and 90

years old, to study whether traumatic brain

injury and/or post-traumatic stress disorder—

both common battlefield injuries—increase the

risk of Alzheimer’s disease later in life.

SPIROMICS Although it is the third-leading cause of death

in the United States, affecting as many as 24

million people, chronic obstructive pulmonary

disease (COPD) is still poorly understood and

treatment options are limited. SPIROMICS, or

SubPopulations and InteRmediate Outcome

Measures In COPD Study, is an observational

study with two main goals. The first is to

identify subpopulations of COPD patients that

share common characteristics. The second is

to identify biomarkers that will enable better

tracking of the disease’s progression. Together,

these efforts should improve the ability of

clinical trials to determine whether particular

therapies are working.

Six university clinical centers are working in

partnership with the National Heart, Lung and

Blood Institute to follow 3,000 COPD sufferers.

Observational Medical Outcomes Partnership America’s drug-approval process has set

the global standard for rigorous safety and

effectiveness review, but even with clinical

trials and other safeguards, it is impossible to

fully understand the impact of any particular

medical intervention until it is widely used.

Once drugs are on the market, researchers

continue to study them to identify safety issues

and potential unanticipated benefits.

In 2007, recognizing that the increased use

of electronic health records and availability of

other large sets of health data provided new

learning opportunities, Congress directed the

Food and Drug Administration (FDA) to create

a new drug surveillance program to more

aggressively identify potential safety issues.

In response, together with PhRMA and the

FDA, FNIH launched the Observational

Medical Outcomes Partnership (OMOP).

This interdisciplinary, public-private research

group is engaged in identifying the most

reliable methods for analyzing huge volumes

of data drawn from heterogeneous sources to

identify drug safety issues. Over the course

of 2011 and 2012, research yielded greater

confidence that particular methods used with

specific types of data can reliably identify

correlations between individual medical

interventions and specific health outcomes.

As experiments continue to provide greater

understanding of how health care data can

be analyzed effectively, OMOP will continue

to evaluate how large-scale empirical

experiments can be refined for maximum

clinical benefit and improved decision-making.

Global Health Collaborating with organizations around

the world, FNIH furthers the understanding

and control of diseases that sicken and kill

hundreds of millions of people every year.

Working in the U.S. and internationally, FNIH-

funded investigators are making strides

against life-threatening diseases including

malaria, dengue, tuberculosis, enteric

infections and malnutrition.

Grand Challenges in Global Health The Grand Challenges in Global Health

(GCGH) is a partnership with the Bill &

Melinda Gates Foundation that fosters

innovative research to address scientific

obstacles that block progress against

diseases prominent in developing countries.

FNIH is involved with several groundbreaking

components of the program.

“Concerning our understanding of the effects of medical products, both benefits and harm, OMOP has demonstrated crucial lessons for pharmacoepidemiology using huge volumes of data. We refined our strategies by selecting the analytical method that produces the greatest accuracy in predicting known health outcomes as well as the method most effective for each data source. We are challenging traditional thinking in epidemiology and exploring new designs.”

David Madigan, Ph.D., OMOP Research Investigator and Professor and Chair of Statistics, Columbia University


The Vector-based Control of Transmission:

Discovery Research (VCTR) program is an

extension of GCGH focused on development

of biologic, genetic or chemical strategies

to control mosquito-borne diseases. In

2012, testing of a promising dengue control

technology that originated in Australia was

expanded to additional field sites in Brazil and

Vietnam. Researchers are working to inhibit

the transmission of dengue virus through

a biocontrol method—infecting the Aedes

mosquitoes that spread the disease with a

bacterium that reduces viral replication in the

mosquito and, consequently, the amount of

virus present in the insects’ saliva to be passed

on when it bites. Australian field trials continue

to compare the effects of different strains of

Wolbachia bacteria on viral development within

the mosquitoes as a marker to predict effects

on dengue transmission.

Investigators in several African countries

joined a consortium working on a new genetic

method to decrease the spread of malaria. The

researchers are developing ways of inserting

an enzyme into Anopheles mosquitoes that

carry the disease. The enzyme will be targeted

to inactivate a gene required for mosquito

reproduction. By inhibiting their capacity

to reproduce, the scientists aim to reduce

mosquito numbers below the level necessary

to maintain malaria transmission.

A completely different approach to interrupting

malaria transmission brings academic and

industry researchers together to screen and

test hundreds of thousands of compounds

for their potential effects on mosquito host-

seeking behavior. Several of the most effective

compounds are already being pursued for

further development, with the goal of creating

better repellents.

Etiology, Risk Factors & Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health & Development (MAL-ED) This partnership with the Bill & Melinda Gates

Foundation and the Fogarty International

Center at NIH, is designed to increase

understanding of the complex interactions

among enteric infections and malnutrition

and their association with impaired growth

and cognitive development and poor vaccine

efficacy in young children.

In February 2012, enrollment was completed

in a large birth cohort study. Researchers

are monitoring nearly 2,000 children—across

eight field sites in rural and urban settings

on three continents—through their first two

years of life. They are collecting and testing a

variety of biospecimens to identify specific risk

factors for growth and development shortfalls.

Early data suggest intriguing differences and

similarities among the sites—valuable insights

that will inform the design of appropriate

interventions.

Identification of High-Quality HITs for Tuberculosis (HIT-TB) This partnership with the Bill & Melinda Gates

Foundation and the National Institute of Allergy

and Infectious Diseases (NIAID), screens

chemical libraries to identify molecules that

could lead to better drugs against tuberculosis.

HIV/AIDS Vaccine Development FNIH serves as the primary awardee for three

research projects that are part of the Bill &

Melinda Gates Foundation’s Collaboration

for AIDS Vaccine Discovery (CAVD). On each

project, the Vaccine Research Center at NIAID

works in collaboration with other institutions to

develop new vaccines to prevent HIV/AIDS.

In 2012, partners at the Vaccine Research

Center made significant progress in

characterizing T and B cell vaccine responses.

A new technology (Fluidigm) allows rapid and

economical screening of hundreds of single

cells for many different markers, facilitating a

more precise understanding of an individual’s

immune status. This advance holds great

promise for expanding the ability to monitor

immune responses to vaccination or infection.

Discussions with the FDA have advanced

planning for a proof-of-concept clinical trial

with the potential to expedite regulatory review

of synthetically designed vaccine inserts.

This three-armed trial will compare wild-type

HIV Env vaccine constructs with mosaic and

consensus constructs to determine relative

safety and efficacy. This approach will facilitate

the design of broadly protective HIV vaccines.

CAVD Projects:The Comprehensive T Cell Vaccine Immune

Monitoring Consortium (CTVIMC), now in

its seventh year, provides standardized,

validated clinical end-point and research

assays for the development and licensure

of a vaccine to prevent AIDS.

The Centralized Envelope Comparative

Immunogenicity Study (CECI) brings together

stakeholders across the Global HIV Vaccine

Enterprise to answer a fundamental and

central question blocking the development

of a successful HIV-1 vaccine: how to design

an AIDS vaccine that will induce protective

cellular immune response against the many

genetically diverse types of HIV-1 that are

found around the world.

The Development of a Second Generation

Broadly Neutralizing Antibody Product to

Prevent HIV-1 Infection in Humans builds

on the recent identification of broadly

neutralizing antibodies in humans that

block the ability of HIV to infect human T

cells. The goal of this project is to optimize

the potency and half-life of monoclonal

antibodies suitable for treatment of HIV/AIDS

and to provide new information for design of

antibody-based vaccines.

Additional Research Partnerships: ADNI Cerebral Spinal Fluid (CSF) Extension

Age-Related Eye Disease Study 2 (AREDS2)

Ancillary Study

Alzheimer’s Disease Neuroimaging Initiative -

Optimization of Alzheimer’s Disease Cognitive

Measures

Placebo Data Analysis Project in Alzheimer’s

Disease/Mild Cognitive Impairment Clinical

Trials (Neuroscience)

Burkitt Lymphoma Genome Sequencing

Project (BLGSP)

Clinical Center Drug Donations

Comparison of Two PET Radioligands to

Quantify the Peripheral Baenodiazepine

Receptor

Development and Production of Endotoxin

under GMP for Human Clinical Research

Drug Induced Liver Injury Network (DILIN)

Epigenetic and Immunoregulatory Control of

Ocular Inflammatory Disease


Evaluation of the Effect of Negative

Costimulatory Signals on the Model of

Experimental Autoimmune Uveitis (EAU) Using

the Ig Fusion Construct AMP-110

Hemodialysis Fistula Maturation Cohort Study

Hereditary Hyperhomocysteinemia–An

Underestimated Disease?

Housing for Chimpanzees Retired from

Biomedical Research

Human Microbiome Project

Demonstration Projects

Human Papilloma Virus Clinical Trial

(HPV-GSK)

Induced Pluripotent Stem Cell Consortia

Measures for Clinical Trials of Treatment of

Cognitive Impairment

Mutational Analysis of the Melanoma Genome

Neurotropin Research Project

Osteoarthritis Biomarkers Project

Osteoarthritis Initiative Extension (OAI 2)

Overcoming Barriers to Early Phase Clinical

Trials

PATH Youth Program: HIV/AIDS in Adolescents

Phase II Trial of IPH2101 (anti-KIR) in

Smoldering Multiple Myeloma

Progressive Multifocal Leukoencephalopathy

Data Registry

Research Partnership in Cognitive Aging

Schizophrenia Metabolic Initiative (SMI-BMS)

Senior Independent Living Research Network

T Regulatory Cells as a Peripheral Marker

for the Development of Age-related Macular

Degeneration (AMD) and Uveitis

Testing for MMTV and Related Retroviruses in

Breast Cancer

Time Efficient Automatic Lesion Identification

and Measurement on CT

Use of Targeted Multiplex Proteomic Strategies

to Identify CSF-Based Biomarkers in

Alzheimer’s Disease

TRAINING AND EDUCATION

“The future promises remarkable advances in

biomedical research. To attain that goal, we

need broad, transformative training for clinician

scientists. It is time to invest boldly in new

ways of learning so that the next generation of

innovative thinkers can open new frontiers in

knowledge and transform medicine.”

Francis Collins, M.D., Ph.D. NIH Director


Medical Research Scholars Program The inaugural class of the Medical Research

Scholars Program began training on the NIH

campus last fall. The program welcomed 45

of the best and brightest young researchers

from 34 medical, dental and veterinary

schools across the country. During the year-

long program, the students conduct basic,

translational or clinical research in a field of

their choice, guided by a mentor and a tutor.

To foster the next generation of medical

researchers and clinician-scientists committed

to translational research and the promise it

holds for the conquest of disease, the program

immerses students in the full continuum of

biomedical research early in their career

training. In addition to their research work,

students complete an academic curriculum

and interact with NIH scientific leaders—

institute directors, clinical directors and

established investigators.

The program merges and builds on two

earlier, highly successful training programs,

the Howard Hughes Medical Institute-NIH

Research Scholars Program and the Clinical

Research Training Program. The goal is to

support 70 scholars each year.

Training and Education While technology plays an increasingly vital role in advancing human health, progress is impossible without a new generation of capable and curious researchers. FNIH programs in various formats target a wide array of topics and education levels, making the world-class methods and resources of the NIH available to students and researchers all over the world.

Additional Training, Education Programs and Fellowships: Bernard Osher Foundation NCCAM

Practitioner Research Career

Development Award

Clinical Research Training Program (CRTP)

Laboratory Animal Medicine Resident

Training Program

NINR Research Fellow Ralph Michael Peace

Oxford Cambridge Scholarship Program

Pew Latin American Fellows Awards

Principles of Clinical Pharmacology Course

Targeting MMP Using Three-dimensional

Culture of Human Breast Cancer

Tracking intracellular nanoparticle dynamics

and cytotoxic/epigenetic signatures both in

vitro and in vivo using advanced cytometry

and multimodal imaging

US-Russia Collaboration in the Biomedical

Sciences Fellowship Program

World AIDS Foundation-Clayton-Dedonder

Scholarships


Human Genome Exhibition Employing the world-renowned expertise of

the Smithsonian Institution to interpret complex

concepts for the general public, a new

exhibition will tell the story of the discovery

of the human genome. A FNIH partnership

with the National Human Genome Research

Institute and the National Museum of Natural

History, the interactive exhibit will open in June

of 2013—the 10th anniversary of the mapping

of the human genome and the 60th anniversary

of the discovery of the double-helix structure

of DNA.

One of the great feats of exploration in history,

the Human Genome Project unlocked a new

dimension in science and healthcare—yet

it remains largely inscrutable to the general

public. Accompanied by a dynamic education

and outreach program, the hands-on exhibit

will trace the history of the project and reveal

the enormous impact genomics has had on

individuals, humanity and the natural world.

Themes will include health and medicine,

ethics, biodiversity, ancestry and what the

future may hold.

After its run of at least one year at the Natural

History Museum in Washington, D.C., the

exhibit will travel nationally, bringing the

wonders of this achievement to thousands

around the U.S.

“Through the exhibition, we aim to help the public see how the Human Genome Project set the stage for the modern era of genomics. With this have come spectacular opportunities for using genomics to expand our knowledge of the human body in health and disease and to understand the underpinnings of biodiversity in the natural world.”

Eric D. Green, M.D., Ph.D., Director, National Human Genome Research Institute

EVENTS

Alzheimer’s Disease Summit

“The FNIH’s support of the Alzheimer’s Disease Summit was instrumental in bringing together over 500 researchers and the advocate community to focus on the way forward in finding treatments for this terrible disorder. The summit fulfilled a major goal of the new National Plan to Address Alzheimer’s Disease, that of convening national and international scientists to identify priorities and milestones to reach our goal of preventing or treating Alzheimer’s by 2025.”

—Kathleen Sebelius, Secretary, Department of Health and Human Services. The Summit was hosted by the Department of Health and Human Services and the National Institute on Aging, with the support of the FNIH.


The Heart Truth®

Marking a decade of educating women aboutMarking a decade of educating women about

the importance of heart health in 2012, Thethe importance of heart health in 2012, The

Heart Truth® campaign has attracted a wide Heart Truth® campaign has attracted a wide

range of support—from individual knitters to range of support—from individual knitters to

large corporations.large corporations.

Education has been shown to be an importantEducation has been shown to be an important

factor in lowering the risk for heart disease.factor in lowering the risk for heart disease.

ute The National Heart, Lung and Blood Institute The National Heart, Lung and Blood Institute

n, reportsportsports(NHLBI), which created the campaign, re(NHLBI), which created the campaign, re

that women who are aware that heart dit diseaset diseasethat women who are aware that hethat women who are aware that he

is the number-one killer of womeomen areomen arethe number-one killer of the number-one killer of

significantly more likely to tato take positiveto take positiveantly more likelyantly more likely

action than those whowho are not.who are not.hoshos

dition to working with sponsors, FNIHIn additioIn additio

s the community action grant administers thadministers th

ad the word—particularly to program to spread tprogram to spread t

rity communities. In 2012, low-income and minoritylow-income and minority

00,000 to five organizations0 to 0 to FNIH awarded $300,0FNIH awarded $300,0

communities from Washington unities frounities froworking in commworking in comm

o Connecnecticut.necticut.State to CState to C

Outreach and fundraising activities included utreach and fundraising autreach and fundraising aOO

Collection—theunveiling of the Red Dress Cunveiling of the Red Dress C

he Heart Truth®Red Dress is a symbol of thRed Dress is a symbol of th

rk Fashion Week campaign—during New Yorcampaign—during New Yor

m created by Jimmyand the Stitch Red programand the Stitch Red program

Beans Wool.Beans Wool.

Additional Events and Outreach Grants: Google Ad GrantGoogle Ad Grant

ute (NCI) SmallThe National Cancer InstituThe National Cancer Institu

arch (SBIR) ForumBusiness Innovation ReseaBusiness Innovation Resea

al Medical SciencesNational Institute of GeneraNational Institute of Genera

Stetten Symposium(NIGMS) 50th Anniversary (NIGMS) 50th Anniversary

nd Disease –Dendritic Cells in Health anDendritic Cells in Health an

nA Tribute to Ralph SteinmaA Tribute to Ralph Steinma

urementAlzheimer’s Disease MeasuAlzheimer’s Disease Measu

enceImprovement ConferenceImprovement Conference

mmitmHealth SummmHealth Summ

IH/FDA Glycosciences Research DayNIH/FNIH/F

Events Collaboration happens when people connect. That is why managing and organizing meetings and events is fundamental to the work of the FNIH. From lectures and workshops to collaborative summits, teleconferences and media opportunities, the FNIH facilitated more than 60 events in 2012—spanning the globe and dozens of fields of research.

FUNDS AND

“Since its founding in 1996, FNIH has raised

almost $700 million for vital programs in health

and biomedical research and has assembled

coalitions that otherwise might never have

been possible.”

Maria Freire, Ph.D., President and Executive Director, FNIH


Named Funds Named funds are created to support specific

areas of research or fellowships, lectures or

awards at the NIH.

Gramlich Melanoma Research Fund This fund supports melanoma research at the

NIH through an annual gift provided by the

Jack Gramlich Foundation.

The Dr. Franklin A. Neva Memorial Fund The Neva Fund was established by the family

of Dr. Frank Neva, a former director of the

NIAID Laboratory of Parasitic Diseases (LPD)

at the NIH, to honor his memory and further

his legacy.

Dr. Neva was keenly interested in teaching and

learning through case-based discussions and

he transformed the LPD into a pre-eminent

center for basic and clinical parasitology

research and training.

Sayer Vision Research Fund This fund supports the annual Sayer Lecture

delivered by an investigator in the area of

vision research, as well as the Sayer Vision

Research Award, given to a promising

independent investigator in the early stage

of his or her research career in the Division

of Intramural Research at the National Eye

Institute. The fund was established by NIH

research scientist Jane Sayer, in honor of her

family and in memory of her parents, Winthrop

and Laura Sayer.

Swanson Family Fellowship The Swanson Family Fellowship supports

research in TTF-1 mutation-causing benign

chorea in the laboratory of infectious diseases

under the direction of Steven M. Holland, M.D.,

Chief of the Laboratory of Clinical Infectious

Diseases, NIAID.

Funds and Endowments Funds and endowments established at the FNIH are a lasting way for individuals and organizations to pay tribute to special people or causes through ongoing support of research, education or events in biomedicine at the National Institutes of Health (NIH). Large or small, such gifts are a testament to the impact every person can make on discoveries that advance human health.

Memorial Funds Memorial funds create a living legacy. In many

cases a family member may request that

friends and relatives make donations—rather

than send flowers—to support a chosen cause

in memory of a loved one. Families may wish

to go one step further and establish a fund

that embodies a loved one’s passion and

spirit by making a significant investment in

the Foundation.

Dr. John L. Barr Memorial Fund This fund helps to support the Intramural

Research Training Award Fellowship Program

at the NIH Clinical Center’s Pain and Palliative

Care Service. The goal of the fellowship is

to conduct research on pain and palliative

care and to encourage young investigators to

become more familiar with the importance of

this field of study.

Adam J. Berry Memorial Fund This fund was established by Michael and

Sue Berry in memory of their beloved son,

Adam. Adam came from Australia to work as

a research scientist at the National Cancer

Institute (NCI). The fund commemorates his

life and his enthusiasm for work by making

it possible for promising young Australian

scientists to travel to the United States and

work at the NIH.

Edna Williams Curl and Myron R. Curl Fund for Multiple Sclerosis Research

Established in 2007, this fund supports multiple

sclerosis research at NIH.

John Laws Decker Memorial Fund

A former director of the NIH Clinical Center, Dr.

John Laws Decker strived during his lifetime

to accelerate important scientific research by

linking research communications around the

world. His dedication led the NIH to establish

an annual lecture in his name. This fund,

established by the Decker family, supports an

event for the lecturer each year.

Dean R. O’Neill Renal Cell Cancer Research Fund

This fund supports a fellowship in the

laboratory of tumor immunology headed

by Richard Childs, M.D., at NHLBI. The

postdoctoral cancer investigator funded by the

program conducts research on the treatment

of renal cell (or kidney) cancer.

Family and friends of the late Dean O’Neill estab-

lished the fund; more information can be found

at www.renalcellcancer.org. The family also orga-

nizes the annual Boo! Run for Life 10K race and

two-mile walk to support the fund. Information

about the Boo! Run, held annually in October,

can be found at www.boorunforlife.com.

Dr. Edward T. Rancic Memorial Fund

This fund supports a post-doctoral fellowship

that focuses on renal cell cancer research in

the laboratory of tumor immunology headed by

Richard Childs, M.D., at NHLBI. The fellowship

was established in memory of Dr. Edward

Rancic by his family.


Dr. Anita Roberts Memorial Fund

Widely recognized as an outstanding mentor,

encouraging and inspiring young scientists,

Dr. Roberts was one of the first female

laboratory chiefs at the NIH and ranked in

the top 50 most-cited biological scientists

in the world. Her family and laboratory

colleagues established the fund to allow

graduate students and post-doctoral fellows

to present their work at a national meeting,

typically the TGF-beta Keystone Symposium.

These scholarships are a fitting tribute to Dr.

Roberts’ passion for encouraging the career

development of young scientists.

Tracy’s Toy Box

Established by the family in memory of Tracy

Nadel, this fund purchases toys and activities

for children staying at the Edmond J. Safra

Family Lodge. These items help make their

time at the Lodge more comfortable

and pleasant.

Robert Whitney Newcomb Memorial Fund This fund was established by the family to

remember Dr. Newcomb, who began his

scientific career at the NIH as a high school

summer intern in a laboratory at the NCI.

The fund endows an annual lecture by a

recognized expert in neuroscience, selected

by the National Institute of Neurological

Disorders and Stroke (NINDS). Honoring Dr.

Newcomb’s own experience, it also provides

for internships for high school students and

fellowships at NINDS.

Stephen J. Solarz Memorial Fund Nina Solarz established this fund in memory

of her husband, former Congressman Steve

Solarz, to support the research of Dr. David

Schrump at NCI. Dr. Schrump’s pioneering

research in the field of thoracic oncology led

to the treatments that allowed Mr. Solarz to

live years beyond what otherwise would have

been possible. Before he died, Nina and her

family dedicated themselves to supporting

Dr. Schrump’s research so that other patients

might benefit by even better treatments.

Stephen E. Straus Fund Established by Bernard and Barbro Osher in

2006, this fund honors the founding director of

the NIH’s National Center for Complementary

and Alternative Medicine (NCCAM), the late Dr.

Stephen E. Straus. It supports the Stephen E.

Straus Distinguished Lecture in the Science

of Complementary and Alternative Medicine,

an annual lecture that brings leading figures

in science and medicine to the NIH to speak

about their perspective on the field. Open

to the public, the lecture is videocast and

archived on the NCCAM website.

Endowments Through these endowment gifts, donors

ensure perpetual support for a variety of

research and educational initiatives at FNIH.

The annual investment income generated by an

endowment fund supports program expenses,

while the principal remains intact to ensure

future funding.

Sallie Rosen Kaplan Fund for Women Scientists in Cancer Research

The Kaplan Fund, established in 2000,

provides support for the Sallie Rosen Kaplan

Fellowships for Women Scientists in Cancer

Research. These post-doctoral fellowships are

awarded to one or more outstanding female

scientists at the NCI.

Norman P. Salzman Memorial Fund Dr. Salzman’s family, colleagues and friends

remember the legacy of this noted pioneer in

molecular biology through contributions to this

fund, which supports the annual Norman P.

Salzman Memorial Award and Symposium in

Virology. The half-day symposium addresses

key topics in virology and immunology and

presents an award to a young researcher, in

recognition of Dr. Salzman’s mentorship of so

many younger scientists.

Endowments in support of the Edmond J. Safra Family Lodge

Through endowment gifts, donors ensure

perpetual support to the Edmond J. Safra

Family Lodge for its operations and for the

continued comfort of its guests.

John I. and Elaine K. Gallin Endowment The Gallin Endowment provides amenities for

family members of patients participating in

clinical trials at the NIH.

GlaxoSmithKline Endowment The GlaxoSmithKline Endowment supports

programs and activities for families, including

services that help residents stay in touch with

employers and loved ones.

Harry and Jeanette Weinberg Endowment The Weinberg Endowment supports

Edmond J. Safra Family Lodge operations

and maintenance—ensuring that guests are

provided a comfortable home away from home

for years to come.

Additional Funds: Jerry D. Jennings Memorial Fund

NCI Neuro Oncology Branch Fund

Pain and Palliative Care Program,

Roxane Institute Fund

Research in Congenital Adrenal Hyperplasia


DONORS AND GIVING SOCIETIES

“…On Monday, 14 May, the Jewels for Hope:

The Collection of Mrs. Lily Safra auction at

Christie’s Geneva was a wonderful success.

Thanks to the sale of this jewelry, the Lily Safra

Foundation will be able to provide $1 million to

each of 32 extraordinary organizations around

the world, and I am delighted that the Edmond J.

Safra Family Lodge at the NIH is among these.”

Mrs. Lily Safra, Chair, Lily Safra Foundation; FNIH Board Member

Donors

$5,000,000+

Bill & Melinda Gates Foundation 11

National Football League

$2,500,000 – $4,999,999

Johnson & Johnson 12

$1,000,000 – 2,499,999

Amgen, Inc. 10

Eli Lilly and Company 13

McKnight Brain Research Foundation 7

Merck Sharp & Dohme Corp.15

Novartis Pharmaceuticals Corporation 13

Pfizer Inc 15

Pharmaceutical Research and Manufacturers of America 8

Mrs. Lily Safra 11

$500,000 – $999,999

Abbott Laboratories 5

AstraZeneca LP 11

Avon Foundation for Women 2

Doris Duke Charitable Foundation 10

Ann Lurie

National Institutes of Health 17

QuantumLeap Healthcare Collaborative 3

Takeda Pharmaceuticals Company Limited 4

$250,000 – $499,999

Alzheimer’s Association 8

Arthritis Foundation, Inc. 3

Bausch & Lomb 2

Biogen Idec 2

Paula L. and William C. Bradley 5

The Brin Wojcicki Foundation

Bristol-Myers Squibb 13

Critical Path Institute and the Predictive Safety Testing Consortium 2

Eisai Inc. 6

GlaxoSmithKline 14

Healthcare Information and Management Systems Society

The Leona M. and Harry B. Helmsley Charitable Trust

Robert Wood Johnson Foundation 9

Nippon Zoki Pharmaceuticals Co., Ltd.

Novo Nordisk A/S 2

The Bernard Osher Foundation 4

Roche 6

The Safeway Foundation 2

Sanofi 11

Temptime Corporation 2

$100,000 – $249,999

Alere Inc. *

Bioiberica S.A. 2

Boehringer Ingelheim Pharmaceuticals, Inc. 5

Celgene Corporation 3

The Coca-Cola Company 5

Daiichi Sankyo, Inc. 3

Elan Pharmaceuticals

Flexion Therapeutics, Inc.

Howard Hughes Medical Institute

Mike and Beth Hunkapiller

IBEX Technologies Inc. *

Immunodiagnostic Systems Holdings PLC *

Institut De Recherches Internationales Servier 3

IXICO Ltd.

NeuroRx

Pacific Biosciences

Piramal Imaging, GmbH 2

Swarovski North America, Ltd. 3

$50,000 – $99,999

American Diabetes Association 3

Amylin Pharmaceuticals, Inc. 3

AXA Research Fund

Peter D. and Karen N. Bell

CTIS Inc. 3

Dairy Research Institute 2

The Dannon Company, Inc. and Nutricia 3

DePuy Mitek, Inc.

Innogenetics N.V.

Joel S. Marcus and Barbara Allenstein Marcus 2

New England Biolabs 4

PhRMA Foundation 5

Promega Corporation 3

SAIC-Frederick, Inc.

SAP America, Inc.

University of Pittsburgh

$25,000 – $49,999

23andMe, Inc.

Actelion Pharmaceuticals Ltd. 2

Alexandria Real Estate Equities, Inc. 2

Amorfix Life Sciences Ltd.

BioClinica, Inc. 3

Biotechnology Industry Organization 5

The Breast Cancer Research Foundation

Burlington Coat Factory

Carestream Health, Inc.

Cubist Pharmaceuticals, Inc. 2

Dell Inc. *

James H. and Christina W. Donovan

Estée Lauder Companies Inc. 2

Forest Laboratories, Inc. 2

Friends of Cancer Research 3

Estate of Jack Gramlich 2

Hogan Lovells * 3

Medpace, Inc. 4

Meso Scale Diagnostics, LLC. 4

Dr. and Mrs. Paul M. Montrone 15

Drs. Martin J. and Ann Murphy 7 In honor of Charles A. Sanders

Nabriva Therapeutics AG 2

Oregon Health & Science University

Qualcomm, Incorporated 4

RottaPharm I Madaus 2

Mr. Gerald R. and Dr. Ellen V. Sigal 10

SoBran, Inc. 2

Susan G. Komen for the Cure

Synarc, Inc. 5

Trius Therapeutics, Inc. 2

The Foundation for the NIH would like to thank the many

corporations, private foundations, associations and

individuals who generously provided financial and in-kind

support to the Foundation and its programs during 2012.

Restricted gifts support many varied initiatives, including

complex biomedical research programs; educational

efforts such as fellowships, lectures and symposia that

train scientists and help them build their careers; and

specific laboratories or areas of scientific research at the

NIH. Unrestricted gifts support core operations and enable

the Foundation to develop emerging program areas and

new partnerships.

The Foundation is very efficient in managing the private

sector’s investment. Of every dollar spent by the

Foundation, 94 cents are used to support programs and

just 6 cents for administration and fundraising. In testament

to the FNIH’s efficient management of your investment,

we have been awarded—for six consecutive years—four

stars by Charity Navigator. This top ranking recognizes that

we execute our mission in a “fiscally responsible way, and

outperform most other charities.” The Foundation gratefully

acknowledges the following donors and partners who

made gifts or pledges of $250 or more during 2012.

The Foundation for the NIH makes every attempt to list

donors according to their wishes. Please call 301.402.5311

if you have any questions.


United HealthCare Services, Inc. 2

George and Trish Vradenburg Co-Founders USAgainst Alzheimer’s

$10,000 – $24,999

Anonymous

Bernard W. Abrams Family Foundation, Inc. 3 In memory of Bernard W. Abrams

Affymetrix

Alliance for Aging Research

American Association for Clinical Chemistry and the Wallace H. Coulter Foundation

AMS Foundation for the Arts, Sciences and Humanities

Elizabeth Arden Spas, Inc.

Autism Speaks, Inc.

Basilea Pharmaceutica International Ltd. 2

Buffy and William Cafritz 9 In honor of Charles A. Sanders

CHDI Foundation

Chiesi Farmaceutici S.p.A. 3

Corgenix Medical Corporation *

Crescendo Bioscience

Stephen P. A. Fodor, Ph.D.

Forest City Enterprises, Inc.

Miles Gilburne and Nina Zolt 3

Grifols

International Biomedical Research Alliance 2

Kite Pharma, Inc.

Legacy Venture V, LLC

Howard H. and Jacqueline K. Levine 2

Freda C. Lewis-Hall, M.D., FAPA 2

Steven C. Mayer

McCann Worldwide

Merck Sharp & Dohme Corp. * 15

National Pharmaceutical Council 2

Erik F. Neva

Kristin Neva

Bob and Sally Newcomb 2

Estate of Jennifer R. Price

Jillian Sackler, D.B.E. 10

Jane M. Sayer, Ph.D. 11

SOHO Publishing Company

Talecris Biotherapeutics, Inc

Joseph M. and Madeline Wikler In honor of John Gallin

$5,000 – $9,999

Anonymous

The Agouron Institute

Arie Belldegrun

Ronald and Barbara Berke 3 In memory of Jennifer Berke

Luther W. Brady, M.D. 6

Esther and James H. Cavanaugh 5

Cempra Pharmaceuticals 2

Ms. Laura Curtin 4 In memory of Richard Curtin

James V. Kimsey

John L. Latka, Jr. In memory of Lillian O. Latka

Life Technologies *

Jean Linton 10

Meridian Hospitals Corporation

Drs. Roslyn and Jerome Meyer

Mohr Davidow Ventures

Morrison & Foerster LLP

Nanticoke Memorial Hospital

Steven and Jann Paul 2

Quidel Corporation *

Radiological Society of North America 4

Skacel Collection

Solomon H. and Elaine B. Snyder 12

Nina Solarz 3 In memory of Stephen Solarz

SunTrust Banks, Inc. 2

United States Pharmacopeial Convention 2

University of British Columbia 2

Steve and Chris Wilsey 5

Stewart K. Wilson In memory of Blaise Ribet

$2,500 - $4,999

Anonymous

American Society For Pharmacology and Equipment Therapuetics

BIO Ventures for Global Health

BioVendor Inc. *

Joseph M. Feczko, M.D. and Leighton K. Gleicher 5

Foundation for Advanced Education in the Sciences

GlaxoSmithKline * 14

Fred and Noreen Hassan 3

Dr. and Mrs. Garry A. Neil

Donna Nichols 3

In memory of Jay NicholsLenore R. Salzman 15

In memory of Dr. Norman P. Salzman

Dr. and Mrs. Charles A. Sanders 16

Simon Property Group 3

The Eddie and Jo Allison Smith Family Foundation 2 In honor of Lanier Swann and Chris Battle

Michael and Lynda S. Swann

In honor of Chris and Dena BattleSamuel O. Thier, M.D. and Paula Thier 7

Ullmann Family Foundation 4

$1,000 – $2,499

Anonymous

Ronald A. and June L. Ahrens

Shana Alexander Charitable Foundation Dr. and Mrs. William G. Barsan 3

Becton Dickinson and Company

The Honorable and Mrs. William McCormick Blair, Jr. 14

Mr. Zachary T. and Dr. Kathy Bloomgarden 4

Boehringer Ingelheim Pharmaceuticals, Inc. * 5

Samuel and Gail Broder 12

Mr. Charles Cerf and Dr. Cynthia E. Dunbar 3

Mark Chee, Ph.D.

Carole Corcoran In memory of Stephen Solarz

Stewart Daniels 4 In memory of Anita Dickler

Robert and Betsey Drucker 2

Amelia Eisch and Shae Padrick In memory of Dr. Rolf H. Joho

The Essence of Red Committee 2

Ronald G. Evens, M.D. 6 In honor of John Gallin

James M. Felser, M.D. 3

Drs. Ernesto I. and Maria C. Freire

Paul J. Gattini

Stanley and Eve Geller 2 In memory of Norman Salzman

Howard Gershenfeld, M.D., Ph.D. In memory of Rolf Joho

Eli Glatstein, M.D. 9

GlycoMimetics, Inc.

GlycoSyn (IRL)

Gary and Lynn Grossman 2

Kay A. Hart 2

Harley Anderson Haynes, M.D. 3

Eric Hirschhorn 2 In memory of Stephen Solarz

Eva C. Holtz 3

IQ Solutions 3

Jen Family Charitable Trust

Jimmy Beans Wool

Daniel L. Kastner, M.D., Ph.D.

Bernard H. and Georgina E. Kaufman 3

The Latin Family In honor of Todd Latin

Jonathan D. Levine 2

Omega C. Logan Silva, M.D., MACP

James and Marie Malaro 2

The Honorable and Mrs. Frederic V. Malek

Miltenyi Biotec, Inc.

Fred and Jakki Nance

Brian R. O’Neill 10

Matthew W. O’Neill 6

Robyn Painter In memory of Jay Nichols

Ron and Joy S. Paul and Family 3 In honor of Fred Sommer’s Birthday

Jared Pellegrini and and Team HOPESTRONG In memory of Matt Koehler

Amy and John Porter 13

Eric K. Ralph

Robert E. Roberts, Ph.D. 4

Estate of Frances H. Saupe 6

Alex and Renee Shumate

Sigma-Aldrich Corporation 4

Sandy and Heidi Sinick

Society for Glycobiology

Fred S. and Nancy T. Sommer 2

Mark A. Spiteri 7

Dr. and Mrs. James R. Stabenau

Joseph and Carole H. Stavenhagen

Stitch Red

The Drs. Tremoulet 4

Trendsetter Yarns

TRQSS Associates In memory of Wesley LaPorte

George F. Vande Woude, Ph.D. 2

Jon and Kristin Vaver 5

Robert J. and Jean S. Warrick

Waters Corporation

Howard M. and Nancye C. Weisberg 4

Robert A. and Peggy A. Welch

$500 – $999

Anonymous

Ann Ashby and Ron Kopicki 2

Association of American Medical Colleges

Berroco, Inc. 2

Tino and Dawn Calabia 2

Dan Balliet and Jan Carlson 4

J.R. Clark and Family

Craig Corbitt and Nancy Stoltz 3

Drs. Paul J. and Faith B. Davis

Janet S. DeGilio 3

Denise Interchangeable Knitting Needles 2

Dreamcatcher Productions, Inc.

Carol and John Eddy 5 In honor of Garth Eddy

Margaret Emery In memory of Wesley LaPorte

Nicholas M. and Jacqueline E. Ferriter 3

Festival Sports, Inc.

James and Karen Gavic 3

Peggy J. Gerlacher 15 In memory of John D. Gerlacher

Ken and Yvette Guidry 6

Mary Frances Cotch and B. Fenton Hall 8

Jennifer D. Hendricks

Jerry Hornstein

Susan Horowitz

Laurel Jacobson 3 In memory of Stephen Jacobson

Michael M. Kaback, M.D.

Charles E. Kaufman Medical Fund

Ronald and Susan Krall

Jeremy Krasner

Erica Joyce Lam

Dr. and Mrs. Ronald W. Lamont-Havers 3

Lantern Moon, Inc.

Ron Levenbaum, D.M.D.

Russell C. Libby, M.D. and Mary Schmidt Libby, M.D.

Jim and Wendy Maiwurm

Mattlin Foundation 4

Anthony B. Mauger

Daniel Mayer

Luke McCrone

Daniel Merced 2

Dr. Gilbert S. Omenn and Mrs. Martha Darling 2

Susanne N. O’Neill

Frank M. and Lillian W. Orson

Premier Yarns Inc.

Armand and Lissette Rodriguez 2

Robert and Marjorie Rosenberg

Alissa Roston

Dr. and Mrs. Howard K. Schachman 8

Tiffany Smith

Dr. and Mrs. Sheldon Spector

Tom and Meg Stanton

Jonathan Taylor In memory of Dennis Taylor

Nitish Thakor

Travelers Companies, Inc.

Joseph Walker and Mary Oates Walker

John P. Walsh and Annette Deshotels

Michael and Marianne Walter 2 In honor of Matt Walter

Gail G. Weinmann

Mrs. Henry P. Wheeler 12

John H. Wilson 4

Brian and Brittany Woolfolk

Laura Zander

$250 – $499

Anonymous

Drs. Bryan and Donna Arling 8

Artyarns

Jill H. Barr 4

In memory of John BarrAnn M. Beck 5

Joan Beck 2

Blue Sky Alpacas

Don and Anne Bordine

In memory of Jan WeymouthAmy Brown

John and Kendra Burlingame

Cambridge Isotope Laboratories, Inc. 3

Larry and Anne Carrick In memory of Wes LaPorte

Daniel Carucci, M.D., M.Sc., Ph.D. 3

Patrick Chin In memory of Enid Chin

Churchmouse Yarns & Teas

Raymond W. Clement 4

Peter Collins, Ph.D. 4

ComputerShare

Peter H. Crawford

Susan G. Davis 4

James P. and Jacqueline M. Dougherty

Margaret Barr Eastman In memory of John Barr

Scott and Anedi Edelstein

Elsevier, Inc. 5

John Ferrara In honor of Nick Silano

Jason and Gloria Garver 6

Caite, Brian, and Benjamin Gilmore 2

Drs. David Golan and Laura Green 2

William D. Goldring In memory of Wesley LaPorte

Joseph Grossman

Katherine J. Guire 2

Joe W. Harris 2

Carolyn H. Hayman In honor of Howard Fine

C.T. and Moira H. Hill In memory of Terry Phillips

Arthur E. Holtz

E.A. Holtzman Foundation 2 In honor of Nina Solarz’s Birthday

Alphonse and Carol Ilekis

Interweave Store

Pamela Jeffcoat 4 In memory of Emma Timcho

Richard Jonas and Katherine Vernot-Jonas 5

Koigu Wool Designs

Johanna L. Kool

In honor of James BalowJody A. Kris

Klaus P. and Lisa M. Kutschke

Ned and Beth Levine

Laurie Levy In honor of Michael Robinson and Hilary Cramer

Dr. Adel A. Mahmoud and Dr. Sally Hodder 3

Herb and Marcia Marks

Dr. Anne Alexander Marshall and Mr. Davis Marshall 8

Roger A. and Barbara Michaels 3

Wilson T. and Christy R. Mistr 2 In honor of Chris Battle

Bayard H. Morrison, III, M.D.

Adam Mullins In memory of Wesley J. Laporte

Jim and Marcia Murphy

Jack Nadler

Namaste Inc.

Reverend and Mrs. Robert H. Naylor 3

Christopher J. Ohlandt

Stephen J. Paulino

Plymouth Yarn Company

Mara Polan 2 In honor of Fred Sommer

William J. Price 3

Dr. Paul Ra In memory of Wesley LaPorte

Christina Reyna 2

James and Lora Rodenberg 3

Tali Rombro In memory of Jane Lochary

Michelle Schumaker 2

Marilyn M. Seastrom

Norma Sessions

Stephen C. Shyne

Walt and Rachel Sirene

The Spence Family

T & C Imports

William Tolentino and Andre Bailey 4

James B. Tucker 5

Julie A. Tune 2

Beth Turetsky

In honor of Nina Solarz’s BirthdayPaula Warrick

Robert C. Watson and Debra D. Petersen3

David Wholley and Mary M. O’Crowley

Ingrid Wiley 4

Howard and Julie Wolf-Rodda 6

Joyce A. Yarington 9

In honor of Chris Harp

Joel Yesley 5

Charles W. Zimmerman 5

Matthew Zimmerman 3

* indicates Gifts in Kind

[superscript] indicates number of years of consecutive giving

Donors (continued)


HONORARIUM GIFTS

You can honor a friend or family member for an important occasion with a gift to

the Foundation for the NIH. It is a wonderful way to send good wishes for a birthday

or anniversary, thanks to a friend or doctor, or congratulations for retirement, a job

well done or graduation. Please include the name and address of the individual

being honored so that acknowledgement of your donation can be sent. In 2012, the

Foundation received gifts in honor of the following individuals.

LEGACY SOCIETY

The Legacy Society recognizes individuals who have informed us that they have

named the Foundation for the NIH as a beneficiary in their will or estate plan. These

legacy gifts can support a specific NIH program, area of research or other identified

need, or they may provide unrestricted support to the Foundation. We thank the

following individuals who have named the Foundation as a beneficiary.

Anonymous

Judy Belous

The Honorable and Mrs. William McCormick Blair, Jr.

Paula L. and William C. Bradley

Buffy and William Cafritz

Patricia S. and Ken Kohlen

Drs. Zell and Emily Kravinsky

Patricia Nowosacki

Estate of Jennifer Price

Robert E. Roberts, Ph.D.

Estate of Frances H. Saupe

Jane M. Sayer, Ph.D.

Dr. and Mrs. Robert F. Wagner

Susan M. Wall, M.D.

MEMORIAL GIFTS

Contributions are given to the Foundation for the NIH at the request of family members

in memory of loved ones. These generous contributions enhance our ability to support

the NIH in its mission to improve health, by forming and facilitating public-private

partnerships for biomedical research, education and training. We extend our sympathies

to the family and friends of those memorialized below.

Bernard W. Abrams

Janet Albright

John H. Allred

Leona Anderson

Julius Axelrod

Stuart Baker

John L. Barr

Karol Bell

Jenny Berke

Deborah R. Boshers

Thurston H. Boyd

Al Butler

Bennett Camhi

Veronica S. Cassell

Enid Chin

Sharon Christenson

Richard Curtin

Frank Delk

Anita Dickler

Tom Doering, Sr.

Maureen Dough

Saundra P. Duboff

Marilyn Feit

Henry Gelfand

John D. Gerlacher

Martin Greenberg

Natalie Greenberg

Alton D. Gutshall

Chris Harp

Donald Helfman

Willard W. Henley

Agneta Hughes

Nicholas P. Humy

Stephen W. Jacobson

Rolf H. Joho

Walter Jud

Roberta Kama

Libby Kamaroff

Meagan Kelly

Thomas J. Kennedy

Matt Koehler

Wesley J. LaPorte

Lillian O. Latka

Karen S. Leo

Stephen Liptak

Jane Lochary

Richard H. Madden

Wanda S. Merriweather

John N. Miller

Stan C. Nebinski

Jay Nichols

Casimir J. Noga, Sr.

Jean S. Noga

Dean R. O’Neill

Terry L. “Chipper” Phillips

John Ramos

Blaise Ribet

Zvenia Romaniw

Kathleen Rudis

Norman P. Salzman

Elmer D. Sattler

Arthur G. Schatzkin

Florence Schoener

Lowell and Yin Schurman

Thomas Sims

Reba Sloane

Stephen Solarz

Nathan W. Synan

Dennis Taylor

Emma Timcho

MOM Wagner

Allison Walden

Janice Weymouth

Thet Win Lwin

Sheldon Wolpin

Deborah Wright

William J. Yates

James E. Balow

Chris Battle

Gennady Bratslavsky

Masako Chen

Emily Chew

Hilary Cramer

Garth M. Eddy

Howard A. Fine

John I. Gallin

Eric Green

Barry Grossman

Rozelle Grossman

Stephanie L. James

Mayer Katz

Nancy Katz

Nicholas Kirincich

Todd Latin

Philip Leder

Russell R. Lonser

Claire Lowther

Miguel Materin

Janet Orloff

Jean Pouyes

Lisa Reinish

Shelly Reinsch

Michael Robinson

Lissette Rodriguez

Saul Roseman

Ann Sanders

Charles A. Sanders

Nick Silano

Rene K. Smith

Nina Solarz

Fred S. Sommer

Lanier Swann

Betsy Templeton

Matt Walter

Stuart H. Yuspa

FINANCIALS

“The Foundation for the National Institutes

of Health is successful because of the depth

of the partnerships we engender — from a

sports organization, knitters, pharmaceutical

companies, foundations, individuals and others.

This diversity allows us to continue to bring

wide-ranging talents to bear on the most

critical health care needs.”

Paul Montrone, Ph.D., Chairman, Perspecta Trust; Executive Chairman and Founding Partner, Liberty Lane Partners; FNIH Board Member


Financial SummaryREVENUE AND SUPPORT 2012 2011

Contributions 57,116,585 53,307,415

Grants 1,338,963 7,184,662

Administrative fee 260,551 336,864

Government appropriations 514,000 486,000

Investment earnings 247,254 83,763

In-kind contributions 250,927 2,037,266

Donated services 41,000 44,892

Other revenue 343,501 -

Reduction of future pledges (1,275,000) -

TOTAL REVENUE AND SUPPORT 58,837,781 63,480,862

EXPENSES AND CHANGES IN NET ASSETS

PROGRAM SERVICESFellowships and training programs 1,325,295 1,486,681

Memorials, awards and events 1,246,180 3,712,399

Capital projects 35,100 38,516

Research partnerships 45,183,190 44,259,013

TOTAL PROGRAM SERVICES 47,789,765 49,496,609

SUPPORTING SERVICES Management and general 3,105,327 2,944,238

Fundraising 145,093 145,190

TOTAL SUPPORTING SERVICES 3,250,420 3,089,428

TOTAL EXPENSES 51,040,185 52,586,037

CHANGE IN NET ASSETS 7,797,596 10,894,825

NET ASSETS BEGINNING OF YEAR 84,432,944 73,538,119

NET ASSETS AT END OF YEAR 92,230,540 84,432,944

2012 REVENUES 2012 EXPENSES

The Foundation’s audited statements are available on request.

Grants 2%Other Revenue 3%

Contributions 95% Research Partnerships 89%

Education and Events 5%

Management and Fundraising 6%

2012 Foundation for the NIH Staff President’s Office Maria C. Freire, Ph.D.President and Executive Director

Ann Ashby, M.B.A.Deputy Executive Director

Michele Jezycki, M.A.O.M.Director, Human Relations(Contractor)

Felicia GrayExecutive Assistant

Elizabeth S. JohnsExecutive AssistantOperations

Kathy GuireOperations Officer

Finance Julie Tune, C.P.A., C.F.E.Chief Financial Officer

Eva CoyneAccounting Manager

Cathy MartinSenior Accountant

Noemi B. RodriguezStaff Accountant

Peggy J. GerlacherOperations Associate

Events and Marketing

Laura PayneDirector

Kai YeeWeb Administrator

Kimberly O’SullivanCommunications Officer

Jolie MakEvents Coordinator

Jasmin MilesEvents Coordinator

Andrea HickmanEvents Coordinator

Development

Julie Wolf-Rodda, M.A.Director, Partnership Development

Andrea Baruchin, Ph. D.Director, NIH Relations

Erika TarverNIH Projects Officer

Rob DruckerPartnership Development Officer

Caite GilmorePartnership Development Officer

Jennifer IlekisPartnership Development Officer

Paris L.A. MoorePartnership Development Officer

Will TolentinoDevelopment Systems Administrator

Annie BradfieldExecutive Assistant

Science Administration

Stephanie James, Ph.D.Director of Science and Director, Grand Challenges in Global Health

Michael Gottlieb, Ph.D.Deputy Director of Science

Dennis Lang, Ph.D.Senior Program Coordinator, MAL-ED(Contractor)

Karen Tountas, Ph.D.Scientific Program Manager, MAL-ED

Susan Powell, M.T.S.Senior Grants Manager

Magda GalindoAssistant Grants Manager

Susan Wiener, M.A.Project Manager, Grand Challenges in Global Health

Gail Levine, M.A., C.R.C.C.Scientific Program Manager, CTC-VIMC

Anna Sambor, M.S.Program Manager

Tiffany FrancisExecutive Assistant

OMOP

Tom Scarnecchia, M.S.Executive Director(Contractor)

Emily Welebob, R.N., M.S.Senior Program Manager(Contractor)

Mark KhayterOMOP Lab Team – Lead Engineer

Biomarkers Consortium

David Wholley, M.A.Director

Maria Vassileva, Ph.D.Scientific Program Manager, Metabolic Disorders

Sonia Pearson-White, Ph.D.Scientific Program Manager, Cancer

Judy Siuciak, Ph.D.Scientific Program Manager, Neuroscience

Steven C. HoffmanScientific Program Manager, Inflammation and Immunity

Jessica RatayClinical Project Manager Cheryl MelencioExecutive Assistant


DESI

GN: D

on S

chaa

f & F

riend

s, In

c. |

ww

w.d

sfrie

nds.

com

2012 Board of DirectorsCharles A. Sanders, M. D. (Chairman)Retired Chairman and CEO, Glaxo, Inc.

Mrs. William McCormick Blair, Jr. (Secretary)Director Emeritus, Albert and Mary Lasker Foundation

Kathy Bloomgarden, Ph.D.Chief Executive Officer, Ruder Finn, Inc.

Mrs. William (Buffy) N. CafritzTrustee, The John F. Kennedy Center for the Performing Arts

Mr. James H. DonovanPartner, Goldman Sachs & CompanyAdjunct Professor, University of VirginiaTrustee, Dana-Farber Cancer Institute

Joseph Feczko, M.D.Retired Senior Vice President and Chief Medical Officer, Pfizer Inc

Maria C. Freire, Ph.D.President and Executive Director, Foundation for the NIH

Mr. Miles GilburneManaging Member, ZG Ventures, LLC

Paul L. Herrling, Ph.D.Chairman, Novartis Institute for Tropical Disease

Ronald L. Krall, M.D.Former Senior Vice President and Chief Medical Officer, GlaxoSmithKline

Sherry LansingChief Executive Officer, The Sherry Lansing Foundation

Freda C. Lewis-Hall, M.D.Chief Medical Officer, Senior Vice President—Chief Medical Office, Pfizer Inc

Edison T. Liu, M.D., Ph.D.President and Chief Executive Officer, The Jackson Laboratory

Ms. Ann LurieLurie Investments, Inc.

Mr. Joel S. MarcusChairman/CEO/President/Founder, Alexandria Real Estate Equities, Inc.

Mr. Steven C. MayerRetired Executive Vice President and Chief Financial Officer, Human Genome SciencesRetired Founder and Chief Executive Officer, CoGenesys, Inc.

Paul M. Montrone, Ph.D. (Treasurer)Chairman, Perspecta Trust

Martin J. Murphy, Jr., Ph.D.Chairman and Chief Executive Officer, AlphaMed Consulting, Inc.

Garry A. Neil, M.D.Partner, Apple Tree PartnersHead, R&D Apple Tree Pharmaceuticals

Steven M. Paul, M.D.Director, Helen and Robert Appel Alzheimer’s Disease Research InstituteProfessor of Neuroscience, Psychiatry, and Neurology, Weill Cornell Medical College

The Honorable John Edward Porter (Vice Chairman for Policy)Hogan Lovells US, LLP

Mrs. Jillian Sackler, D.B.E.President and Chief Executive Officer, AMS Foundation for the Arts, Sciences and Humanities

Lily SafraChairwoman, The Edmond J. Safra Philanthropic Foundation

Ellen V. Sigal, Ph.D.Chairperson and Founder, Friends of Cancer Research

Solomon H. Snyder, M. D. (Vice Chairman for Science)Distinguished Service Professor of Neuroscience, Pharmacology & Psychiatry, Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine

Ms. Nina K. SolarzFormer Executive Director, Peace Links and the Fund for Peace

Samuel O. Thier, M.D.Professor of Medicine and Health Care Policy, Emeritus, Harvard Medical School, Massachusetts General Hospital

Anne WojcickiCo-Founder, 23andMe

Honorary Directors

Luther W. Brady, M.D.Distinguished University Professor, Hylda Cohn / American Cancer SocietyProfessor of Clinical Oncology, and Professor, Department of Radiation Oncology, Drexel University College of Medicine

Patrick C. Walsh, M.D.University Distinguished Service Professor, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions

Director Emeritus

Paul Berg, Ph.D.Cahill Professor in Biochemistry (Emeritus), Stanford University School of Medicine

Ex Officio Non-Voting Directors

Francis S. Collins, M.D., Ph.D.Director, National Institutes of Health

Margaret Hamburg, M.D.Commissioner, Food and Drug Administration

Partners for Innovation, Discovery, Health

9650 Rockville Pike Bethesda, MD 20814-3999 USA

301.402.5311

www.fnih.org

All rights reserved. This material may be quoted or reproduced without charge for noncommercial purposes only; however, please acknowledge the source.

The full text of this report is also available online at www.fnih.orgPrinted on Rolland Enviro100 Satin, which contains 100% post-consumer fiber, is EcoLogo and is Processed Chlorine Free certified.

100%

2012 fnih annual report

Documents

neutral convener

partners fromin

nonmany institutes

channthis pivotal position

common challeesources

common challenges

technthe private sector

multiple aesources